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Abstract
Objective: This study was performed to investigate the
impact of HAART versus no HAART and nucleoside
free versus nucleoside containing HAART on the effi-
cacy and safety of pegylated interferon and ribavirin
therapy for the treatment of chronic Hcv infection in
HIv/Hcv co-infected patients. In addition a control
group  of  Hcv  mono-infected  patients  undergoing
anti-Hcv therapy was evaluated.
Methods: Multicenter, partially randomized, controlled
clinical trial. HIv-negative and -positive patients with
chronic Hcv infection were treated with pegylated in-
terferon alfa-2a and ribavirin (800 – 1200 mg/day) for
24 – 48 weeks in one of four treatment arms: HIv-
negative (A), HIv-positive without HAART (B) and
HIv-positive on HAART (c). Patients within arm c
were randomized to receive open label either a nucleo-
side  containing  (c1)  or  a  nucleoside  free  HAART
(c2). 
Results: 168 patients were available for analysis. By in-
tent-to-treat  analysis  similar  sustained  virological  re-
sponse rates (SvR, negative Hcv-RnA 24 weeks after
the end of therapy) were observed comparing HIv-
negative  and  -positive  patients  (54%  vs.  54%,  p  =
1.000). Among HIv-positive patients SvR rates were
similar between patients off and on HAART (57% vs.
52%, p = 0.708). Higher SvR rates were observed in
patients on a nucleoside free HAART compared to pa-
tients  on  a  nucleoside  containing  HAART,  though
confounding could not be ruled out and in the intent-
to-treat analysis the difference was not statistically sig-
nificant (64% vs. 46%, p = 0.209).
Conclusions: Similar response rates for Hcv therapy
can be achieved in HIv-positive and -negative patients.
Patients on nucleoside free HAART reached at least
equal rates of sustained virological response compared
to patients on standard HAART. 
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InTRoducTIon
In Europe up to 33% of the HIv-positive patients are
co-infected  with  hepatitis  c  virus  (Hcv)  [1,  2].  In
Hcv/HIv  co-infected  patients  liver-related  disease
has emerged as a leading cause of morbidity and mor-
tality [3]. The progression of chronic Hcv infection
to liver cirrhosis, liver failure and development of he-
patocellular  carcinoma  is  substantially  accelerated  in
HIv/Hcv co-infected compared to Hcv mono-in-
fected individuals [4]. Successful treatment of chronic
hepatitis c infection with pegylated interferon and rib-
avirin  combination  therapy  has  been  shown  to  stop
progression of fibrosis and prevent liver related dis-
ease and death [5], but treatment of Hcv in HIv co-
infected  individuals  is  complicated  by  additive  drug
toxicities of ribavirin and the nucleoside reverse tran-
scriptase inhibitors didanosine [6, 7], zidovudine [8-11]
and stavudine [12]. furthermore, competitive intracel-
lular phosphorylation of abacavir and ribavirin has re-
cently been hypothesized to further compromise the
efficacy of Hcv treatment in the coinfected host [13-
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of ribavirin [14-16]. 
In the current study we aimed to investigate the im-
pact  of  HIv-1  infection,  nucleoside  containing  and
nucleoside free HAART on the efficacy and safety of
pegylated interferon and ribavirin combination thera-
py for the treatment of chronic Hcv infection. 
METHodS
Study  design:  fifty  HIv-seronegative  and  118  HIv-
seropositive patients with chronic Hcv infection were
enrolled  into  this  multicenter,  prospective,  partially
randomized, controlled trial (fig. 1). HIv-positive pa-
tients with a cd4 cell-count > 300/ﾵl, an HIv-RnA
< 40.000 copies/ml and no indication for HAART re-
ceived  anti-Hcv  therapy  without  concomitant
HAART. HIv-positive patients that either required to
be started on HAART or who were already receiving
HAART were randomized prior to commencing anti-
Hcv therapy into one of two groups: nucleoside con-
taining HAART (c1) or nucleoside free HAART (c2).
If  randomization  required  a  change  in  the  HAART
regimen  or  if  a  patient  was  newly  commenced  on
HAART, a 12 week lead-in phase preceded the initia-
tion  of  anti-Hcv  therapy  to  ensure  stable  HAART
and to differentiate adverse events caused by HAART
and anti-Hcv therapy. due to the risk of severe pan-
creatitis under concomitant ribavirin therapy, didano-
sine was not allowed as part of HAART. Practitioners
were  free  to  construct  a  nucleoside-free  HAART
based on the patientﾴs genotypic resistance assay and
HAART history. A boosted double protease inhibitor
or non-nucleoside reverse transcriptase inhibitor plus
boosted protease inhibitor were recommended as op-
tions  for  a  nucleoside-free  HAART.  The  study  had
been reviewed by the ethics committee of Bonn uni-
versity  and  was  conducted  in  agreement  with  good
clinical practice and the declaration of Helsinki and its
subsequent revisions.
Definitions  and  major  inclusion/exclusion  criteria:
chronic  Hcv  infection  was  defined  as  2  positive
Hcv-RnA tests at least 6 month apart. In order to be
eligible for enrollment, patients had to be na￯ve to in-
terferon-based anti-Hcv therapy, with positive serum
Hcv-RnA  and  elevated  alanine  aminotransferase
(AlT) at screening, to be between 18 and 60 years of
age and given written informed consent. Women or
men  with  female  partners  of  child-bearing  age  not
willing  to  use  two  contraceptive  measures  (one  of
these  had  to  be  a  barrier  method)  and  pregnant  or
breast-feeding women were excluded from participa-
tion. Patients with advanced liver cirrhosis (cHIld-
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Fig.1. Allocation to treatment and follow-up. data shown as numbers (%) of patients.
Disposition of patients
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not  allowed  to  participate  in  this  trial.  Hepatitis  B
virus co-infection, chronic alcohol or illicit drug abuse,
hemochromatosis, other acute or chronic liver disease
and contraindications for pegylated interferon / rib-
avirin combination therapy were further exclusion cri-
teria.
Anti-HCV therapy: All patients were treated with pe-
gylated  interferon  alfa-2a  180  ﾵg  given  once  weekly
subcutaneously. Ribavirin was dosed 800 mg /day for
genotype 2 and 3 infections and weight adapted (< 75
kg bodyweight 1000 mg /day, ≥ 75 kg 1200 mg /day)
for genotype 1 and 4 infections, divided in two doses
per os. HIv-positive patients on HAART received 800
mg ribavirin / day regardless of Hcv-genotype. dura-
tion of therapy was 48 weeks for genotype 1 and 4 in-
fections and 24 weeks for genotype 2 and 3 infections.
The study protocol was amended twice in order to ac-
count  for  recent  results  of  APRIcoT  [17],  AcTg
A5071 [18] and the Ribavic [19] trial, leading to updat-
ed treatment recommendations for HIv/Hcv co-in-
fection  [20].  Amendment  I  (March  2004)  prolonged
duration  of  therapy  for  HIv/Hcv  co-infected  pa-
tients with genotype 2 or 3 infections to 48 weeks and
amendment  II  (october  2004)  prescribed  weight-
based ribavirin for HIv-infected patients with geno-
type 1 and 4 infections and issued a warning on the
concomitant use of zidovudine and ribavirin and asso-
ciated higher rates of anemia.
Virological  response: Response to treatment was de-
fined  as  early  virological  response  (EvR,  decay  of
Hcv-RnA  of  at  least  2  log10 at  week  12  of  treat-
ment),  end  of  treatment  response  (ETR,  negative
Hcv-RnA at the end of treatment) and sustained vi-
rological  response  (SvR,  negative  Hcv-RnA  24
weeks after the end of therapy). levels of Hcv-RnA
were  measured  locally  with  approved  commercial 
assays,  i.e.  versant  Hcv  bdnA  v3.0  (versant, 
Bayer  diagnostics,  Tarrytown,  ny,  uSA),  coBAS
Amplicor Hcv Monitor v2.0 (Roche diagnostics, In-
dianapolis, In, uSA), or Abbott RealTime Assay (Ab-
bott Molecular Inc., des Plaines, Il, uSA). A com-
mon lower cut-off of 600 Iu/ml Hcv-RnA was set
for analysis and a negative Hcv-RnA was defined as
any value < 600 Iu/ml. Hcv genotypes were deter-
mined  locally  with  the  approved  and  commercially
available  Inno-liPA  Hcv  II  (Innogenetics,  gent,
Belgium).
Statistics: The recruitment goal for the study was 200
patients in 4 study arms (50 patients per arm). Primary
endpoint of the study was the difference of the rate of
SvR within study arms c1 and c2 by intent-to-treat
analysis. The study was powered to detect a 25% dif-
ference in the rate of SvR with a p < 0.05 and power
of 80%. Analysis was performed intent-to-treat or as-
treated,  classifying  missing  information  as  equal  to
failure. non-parametric tests were used for statistical
comparison, multivariate regression analysis was per-
formed using a logistic binary regression with a condi-
tional forward model. A two-sided p-value < 0.05 was
considered statistically significant.
RESulTS
dEMogRAPHIc cHARAcTERISTIcS of PATIEnTS
overall 189 patients were screened. Twenty-one sub-
jects  did  not  meet  inclusion  /  exclusion  criteria  or
withdrew  consent  prior  start  of  anti-Hcv  therapy
leaving 168 patients for final analysis (fig. 1). despite
a 1:1 randomization within treatment arm c, an un-
even proportion of patients received at least one dose
of study medication, i.e. 49 patients within the treat-
ment arm c1 and 20 patients within treatment arm c2
started treatment. This was mainly due to unwilling-
ness  of  patients  randomized  to  a  nucleoside  free
HAART  to  change  to  or  start  a  nucleoside  free
HAART (withdrawal of consent, n = 8) or protocol
violation and proceeding with a nucleoside containing
HAART  despite  being  randomized  to  a  nucleoside
free HAART (n = 9). comparing HIv-negative with
HIv-positive patients at baseline age, serum levels of
alanine  aminotransferase  (AlT)  and  Hcv-RnA  and
Hcv genotype distribution were similar between HIv-
positive and HIv-negative patients (Table 1). 
comparing HIv-positive patients across treatment
arms  as  treated,  patients  without  HAART  were
younger than patients on HAART (39 vs. 42 vs. 43
years, p = 0.006) and had higher absolute cd4-cell-
counts (580 /ﾵl vs. 491 /ﾵl vs. 390 /ﾵl, p = 0.008), in
part  reflecting  the  natural  course  of  HIv-infection
(Table  1).  level  of  AlT  and  Hcv-RnA  and  Hcv
genotype distribution did not vary significantly across
HIv-positive treatment groups. Patients in the nucle-
os(t)ide  reverse  transcriptase  inhibitor  (nRTI)  free
arm  were  mostly  on  double  protease  inhibitor
HAART (n = 17), two patients received lopinavir/ri-
tonavir  monotherapy  and  one  patient  was  on
lopinavir/ritonavir and efavirenz combination therapy.
Patients in the nRTI-containing arm received a pro-
tease inhibitor based HAART in 57% of cases; nRTIs
most frequently used were lamivudine or emtricitabine
(98%), followed by tenofovir (47%), zidovudine (33%)
or abacavir (31%).
TREATMEnT cHARAcTERISTIcS
Patients were recruited in germany from 13 tertiary
care centers and 14 private practices. The recruitment
period  lasted  5  years  with  the  first  patient  starting
treatment in August 2002 and the last patient in no-
vember  2007.  Recruitment  of  patients  was  slow  for
the treatment arm c and accordingly there was a sig-
nificant  difference  in  the  proportion  of  patients  re-
cruited within the first half of the recruitment period
(2002 – 2004) compared to the second half (2005 –
2007). HIv-negative patients were all recruited within
the first period, whereas 38% of HIv-positive patients
were recruited within the second period (p < 0.001,
Table 2). Recruitment times varied also across HIv-
positive treatment arms with arm B recruiting fastest
(80% of patients within first period vs. arm c1 55%
vs. arm c2 30%, p < 0.001). due to differences in re-
cruitment  times  we  assessed  whether  there  was  any
difference in the treatment according to the protocol
amendments I and II. As per protocol HIv-negative
patients were treated different than HIv-positive pa-
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tients  with  Hcv  genotype  1/4  infection  received
weight  based  ribavirin  and  all  patients  with  Hcv
genotype  2/3  infections  were  treated  for  24  weeks
only. This was significantly different from HIv-posi-
tive patients (Table 2). Among HIv-positive patients,
no  marked  differences  with  regard  to  the  use  of
weight  based  ribavirin  for  the  treatment  of  Hcv
genotype  1/4  infections  or  prolonged  treatment  of
Hcv genotype 2 / 3 infections were observed. 
TREATMEnT ModIfIcATIonS And AdvERSE EvEnTS
Adverse events were common among all study partici-
pants,  however,  only  19  patients  discontinued  anti-
Hcv therapy because of interferon or ribavirin asso-
ciated adverse events (Table 3). HIv-negative patients
suffered less often from moderate or severe leucope-
nia (WHo grade 3/4) compared to HIv-positive pa-
tients (0% vs. 9%, p = 0.034), however, they also more
often received dose reductions of pegylated interferon
or  ribavirin  (22%  vs.  10%,  p  =  0.048  and  28%  vs.
16%, trend p = 0.087). Among HIv-positive patients
mild AlT elevations, anemia and leucopenia (all WHo
grade  1/2)  were  more  common  among  patients  on
HAART compared to patients without HAART (Table
3). However, dose reductions of pegylated interferon
or ribavirin and premature treatment discontinuation
due to adverse events were not different among HIv-
positive patients.
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Table 1. Baseline characteristics of patients according to treatment arm.
HIV-negative HIV-positive
No HAART NRTI-containing NRTI-free
Arm A Arm B Arm C1 Arm C2
n = 50 n = 49 n = 49 n = 20
Age [years]** 41 (25 – 55) 39 (24 – 47) 42 (30 – 47) 43 (34 – 61)
Male sex* [%] 60  74  76  85
Transmission risk [%]
IVDU 40 33 25 5
Blood products 10 28-
Sexual 82 10 10
other 82--
unknown / missing 34 61 57 85
HCV-genotype [%]
1 52 51 51 50
2 6845
3 38 27 31 40
4 -8 10 5
other 442-
untypable -22-
HCV-RNA [IU/ml, log10] 5.7 (4.5 – 6.8) 5.7 (4.1 – 6.7) 5.5 (4.4 – 6.8) 5.9 (4.3 – 7.3)
≥ 500 000 IU/ml [%] 56  57  41  65 
ALT [IU/l] 61 (21 - 179) 68 (17 – 212) 71 (30 – 221) 75 (26 – 231)
HAART [%]
PI / NNRTI / 3 x NUC -- 57 / 29 / 12 95 / 5 / 0
AZT 33 -
d4T 18 -
ABC 31 -
3TC / FTC 98 -
TDF 47 -
HIV-RNA [copies/ml, log10]** - 3.9 (1.9 – 4.9) 1.7 (1.7 – 3.5) 1.7 (1.7 – 4.5)
CD4-cellcount
[/ﾵl]** - 580 (301 – 1042) 491 (222 – 781) 390 (152 – 846)
[%] - 27 (15 – 41) 27 (13 – 40) 22 (16 – 41)
* Statistically significant difference comparing arm A with arms B and c (HIv-positive vs. HIv-negative)
** Statistically significant difference comparing arm B versus c1 versus c2 
data shown as percent of patients or median (95% range). NRTI nucleos(t)ide reverse transcriptase inhibitor, IVDU intra-
venous drug abuse, other double infections, e.g. genotype 1 and 2 infection; PI protease inhibitor containing HAART, NNRTI
non-nucleoside reverse transcriptase inhibitor containing HAART, 3xNUC HAART based on at least 3 nucleos(t)ides, AZT zi-
dovudine, d4T stavudine, ABC abacavir, TDF tenofovir df
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Table 2. Anti-Hcv Treatment characteristics of patients according to treatment arm.
HIV-negative HIV-positive
No HAART NRTI-containing NRTI-free
Arm A Arm B Arm C1 Arm C2
n = 50 n = 49 n = 49 n = 20
Weight adapted RBV * 96  81  77  82 
(GT1/4 infections only)
Treatment duration 48 weeks  0  35  35  67 
(GT 2/3 infections only) *
Enrollment period */ **
2002 - 2004 100 80 55 30
2005 - 2007 - 20 43 70
* Statistically significant difference comparing arm A with arms B and c (HIv-positive vs. HIv-negative)
** Statistically significant difference comparing arm B versus c1 versus c2 
data shown as percent of patients 
NRTI nucleos(t)ide reverse transcriptase inhibitor, GT Hcv genotype, RBV ribavirin
Table 3. Treatment modifications and selected adverse events under therapy.
HIV-negative HIV-positive
No HAART NRTI-containing NRTI-free
Arm A Arm B Arm C1 Arm C2
n = 50 n = 49 n = 49 n = 20
Elevations serum ALT [%]
Grade 1/2** 64 61 78 90
Grade 3/4 - 10 65
Anemia [%]
Grade 1/2** 10 2 22 5
Grade 3/4 ----
Maximum Hb loss [g/dl] 3.1 (1.1 – 5.1) 3.0 (0.6 – 5.3) 2.9 (0.8 – 5.7) 3.3 (0.8 – 4.4)
Leucopenia [%]
Grade 1/2** 40 25 69 55
Grade 3/4* 04 12 10
Thrombocytopenia [%]
Grade 1/2 44 35 51 55
Grade 3/4 4- 10 5
Clinical adverse events [%]
Grade 1/2 70 63 63 90
Grade 3/4 12 18 85
Dose reduction PegIFN [%]†* 22 8 14 5
% of total dose received 84 87  81  88
Dose reduction RBV [%]† 28 8 25 15
% of total dose received 86  81  79  90
Treatment discont. AEs [%] 8  18  8  10
* Statistically significant difference comparing arm A with arms B and c (HIv-positive vs. HIv-negative)
** Statistically significant difference comparing arm B versus c1 versus c2 
†Percent of patients who were dose reduced for pegylated interferon (PegIfn) or ribavirin (RBv) and respective percent of the
cumulative dose received. 
data shown as percent of patients or median (95% range)
nRTI nucleos(t)ide reverse transcriptase inhibitor, ALT serum alanine aminotransferase, Treatment discont. AEs Treatment
discontinuation due to adverse events.
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overall an early virological response (at least a 2-log
decay of Hcv-RnA at week 12) was observed in 77%
of patients. An end of treatment response (negative
Hcv-RnA at the end of treatment, ETR) was reached
in 70% and was sustained in 54% of patients (SvR,
sustained virological response, negative Hcv-RnA 24
weeks after the end of treatment). Rates of SvR were
comparable  comparing  HIv-negative  and  HIv-posi-
tive patients (54% vs. 54%, p = 1.000, fig. 2a). HIv-
positive patients treatment response rates were higher
in patients on nRTI-free HAART compared to those
with nRTI-containing HAART, which was statistically
significant with regard to SvR in the as-treated analy-
sis (75% vs. 43%, p = 0.019, fig. 2a). Taking into ac-
count protocol violations and analyzing response rates
according to intent-to-treat (analyzed as randomized,
screen failures excluded, missing = failure) a 20% dif-
ference in the rate of response between nucleoside-
free  and  nucleoside  containing  HAART  was  main-
tained, though the difference was no longer statistical-
ly  significant  (nRTI-free  62%  vs.  nRTI  containing
44%, p = 0.209, fig. 2b).
PoTEnTIAl confoundERS And PoST-Hoc AnAlySIS
of TREATMEnT ARM c1
Because treatment arms differed with regard to base-
line characteristics we performed a separate analysis to
investigate  into  the  effect  of  potential  confounders
among  HIv-positive  patients.  Patient  characteristics
found to be different at baseline across HIv-positive
treatment  arms  and  other  known  potential  con-
founders were included in this uni- and multivariate
analysis (Table 4). Hcv-genotype 1 or 4, a high Hcv
viral  load  at  baseline,  taking  an  nRTI  containing
HAART or having to stop anti-Hcv therapy prema-
turely due to adverse events were all associated with
reduced odds of achieving SvR. Patients treated with-
in treatment arm c1 who were on an nRTI containing
regimen,  had  only  30%  the  odds  of  achieving  SvR
compared to the other patients receiving no or nRTI
free HAART (95% cI 10% - 90%, p = 0.025).
In order to further understand the significantly re-
duced rate of SvR of patients within treatment arm
c1 we analyzed this group of patients with regard to
the outcome SvR (Table 5). given the limitation of
small groups, only Hcv genotype 1 or 4 infection and
the level of Hcv-RnA were significantly associated
with reaching SvR. While patients with Hcv geno-
type 1 or 4 infection only reached an SvR in 29% of
patients, an SvR was reached in 71% of patients with
Hcv genotype 2 or 3 infections (p = 0.007). likewise,
the level of Hcv-RnA was significantly higher in pa-
tients without SvR (5.7 vs. 5.1 log, p = 0.001). How-
ever, some characteristics showed marked differences
(20 or more percent difference) whilst not being statis-
tically significant different. Among these were the use
of weight adapted ribavirin in case of genotype 1 or 4
infections (100% vs. 68%), a longer duration of thera-
py in case of genotype 2 or 3 infection (42% vs. 20%)
and the use of abacavir containing HAART (19% vs.
39%).  Indeed  applying  post-hoc  power  analysis,  the
power to detect a significant difference with regard to
the use of abacavir was only 24% and thus further
studies particularly addressed to investigate into these
issues are warranted.
dIScuSSIon
In  this  large,  prospective  and  partially  randomized
study  we  were  able  to  show,  for  the  first  time  in  a
head-to-head comparison, that anti-Hcv therapy may
be applied to HIv-positive patients with the same effi-
cacy  as  to  HIv-negative  patients.  The  SvR  rate  of
54%, as observed among HIv-negative patients in our
trial, is well within the range reported from the regis-
trational trials of pegylated interferon alfa-2a and -2b,
who reported SvR-rates of 54% [21] and 56% [22],
when given in combination with ribavirin. 
The overall rate of SvR reached among HIv-posi-
tive patients within our study is one of the highest re-
ported in HIv-positive patients [17-19, 23-28]. In part,
the high response rates observed can be accounted for
by the introduction of weight based ribavirin for the
treatment  of  genotype  1  and  4  infections  and  pro-
longed treatment of genotype 2 and 3 infections for
48 weeks, which is in contrast to earlier studies and
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Fig. 2a. Rates of virological response according to treatment
group, as treated, missing = failure. EvR early virological re-
sponse (at least 2 log decay of Hcv-RnA at week 12), ETR
end of treatment response (negative Hcv-RnA at the end of
treatment), SvR sustained virological response.
Fig.2b. Rates of virological response according to treatment
group, intent-to-treat, missing = failure. EvR early virological
response (at least 2 log decay of Hcv-RnA at week 12), ETR
end of treatment response (negative Hcv-RnA at the end of
treatment), SvR sustained virological response.
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comparing our results with more recent trials and co-
horts who have used weight-based ribavirin and longer
treatment schedules [26-28] our results are within the
range reported by others (54% vs. 44 – 50%). 
The study was designed to examine different treat-
ment settings of HIv infection and their impact on
the treatment efficacy and safety of pegylated interfer-
on  and  ribavirin  therapy.  our  results  show  that  pa-
tients not receiving HAART achieved similar response
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Table 4. Adjusting effects for possible confounders – SvR, HIv-positive patients.
SVR No SVR Uni-variate Multi-variate Multivariate
n = 64 n = 54 p-value p-value
Odds-ratio (95% CI)
Age [years] 40 (27 – 54) 41 (27 – 48) 0.566 --
Male sex [%] 75  78  0.662 --
Transm. risk IVDU [%] 20  30  0.709 --
HCV GT 1 or 4 [%] 50  76  0.002 0.001 0.2 (0.1 – 0.5)
HCVRNA ≥ 5x105 IU/ml[%] 42 63  0.014 0.009 0.3 (0.1 – 0.7)
ALT [IU/l] 63 (19 – 190) 80 (25 – 250) 0.368 --
Weight adapted RBV [%] 88  73  0.237 --
Tx duration 48 wks [%] 47  27  0.309 --
Enrollment period [%]
2002 - 2004 56 67 0.253 --
2005 - 2007 44 32
Treatment arm [%]
B (no HAART) 44 39
C1 (NRTI-cont.) 33 52 0.047 0.025 0.3 (0.1 – 0.9)*
C2 (NRTI free) 23 9
HIV-RNA [copies/ml, log10] 1.7 (1.7 – 4.8) 1.7 (1.7 – 4.8) 0.372 -
CD4-cellcount 
[/ﾵl] 487 (236 – 1042) 542 (222 – 831) 0.828 -
[%] 27 (15 – 41) 26 (12 – 41) 0.364 -
Anemia [%]
Grade 1/2 11 11 1.000 .
Grade 3/4 --
Leucopenia [%]
Grade 1/2 47 41 0.578 -
Grade 3/4 97 0.753
Thrombocytopenia [%]
Grade 1/2 47 43 0.712 -
Grade 3/4 56 1.000
Clinical adverse events [%]
Grade 1/2 67 69 1.000 -
Grade 3/4 11 13 0.781
Dose reduction PegIFN [%] 11  9  1.000 -
Dose reduction RBV [%] 13  20  0.215 -
Treatm. discont. AEs [%] 5  24  0.003 0.004 0.1 (0 – 0.5)
data shown as percent of patientsor median (95% range); *treatment arm c1 compared to B and c2 (reference)
SvR sustained virological response, Ivdu intravenous drug abuse, gT Hcv genotype; AlT serum alanine aminotransferase,
RBv ribavirin, Tx Treatment, wks weeks, nRTI nucleos(t)ide reverse transcriptase inhibitor, Treatment discont. AEs Treat-
ment discontinuation due to adverse events.
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Table 5. Post-hoc analysis treatment arm c1 with regard to SvR.
SVR No SVR p-value
n = 21 n = 28
Age [years] 41 (31 – 47) 42 (27 – 47) 0.732
Male sex [%] 81  71  0.733
Transmission risk IVDU [%] 19 29  0.844
HCV genotype 1 or 4 [%] 43  79  0.007
HCV-RNA [IU/ml, log10]
HCV-RNA ≥ 500 000 IU/ml [%] 5.1 (4 – 6) 5.7 (4.7 – 7.2) 0.001
24  54 0.019
ALT [IU/l] 72 (31 – 206) 71 (27 – 243) 0.949
Weight adapted RBV, GT 1/4 infections only [%] 100  68  0.141
Tx duration 48 wks, GT 2/3 infections only [%] 42  20  0.600
Enrollment period 2002 – 2004 [%] 52  57  0.771
HAART [%]
3 x NRTI 10 14 0.688
AZT 24 39 0.359
d4T 19 18 1.000
ABC 19 39 0.210
TDF 52 43 0.572
HIV-RNA > Lod [%] 4  14  0.369
CD4-cellcount [/ﾵl] 470 (268 – 685) 524 (222 – 781) 0.521
Elevations serum ALT [%]
Grade 1/2 76 79 1.000
Grade 3/4 - 11 0.250
Anemia [%]
Grade 1/2 24 21 1.000
Grade 3/4 -- -
Leucopenia [%]
Grade 1/2 57 61 1.000
Grade 3/4 14 11 1.000
Thrombocytopenia [%]
Grade 1/2 57 46 0.567
Grade 3/4 9 11 1.000
Clinical adverse events [%]
Grade 1/2 67 61 0.769
Grade 3/4 10 7 1.000
Dose reduction PegIFN [%]† 10 18 0.436
% of total dose received 87 81
Dose reduction RBV [%]† 14 32 0.179
% of total dose received 91 78
Treatment discont. AEs [%] - 14  0.125
†Percent of patients who were dose reduced for pegylated interferon (PegIfn) or ribavirin (RBv) and respective percent of the
cumulative dose received. 
data shown as percent of patients (95% confidence Interval) or median (95% range). SVR sustained virological response,
IVDU intravenous drug abuse, ALT serum alanine aminotransferase, RBv ribavirin, GT Hcv genotype, Tx Treatment, wks
weeks, NRTI nucleos(t)ide reverse transcriptase inhibitor, AZT zidovudine, d4T stavudine, ABC abacavir, TDF tenofovir df,
Lod level of detection, Treatment discont. AEs Treatment discontinuation due to adverse events.
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HAART  (57%  vs.  52%)  while  suffering  less  often
from  anemia  and  leucopenia.  Patients  on  HAART
showed marked differences in rates of response. Pa-
tients  on  nRTI-free  HAART  achieved  significantly
more often SvR compared to patients on nRTI-con-
taining  regimens  (75%  vs.  43%,  p  =  0.019).  Even
though the difference in SvR is impressive caveats on
this finding must be issued, particularly in the nucleo-
side free arm as those patients achieved even higher
SvR rates than HIv-negative patients. despite a 1:1
randomization  to  the  HAART  treatment  arm,  there
was an uneven distribution of patients who actually
started on a nucleoside free and nucleoside containing
HAART.  Reason  for  this  was  mainly  withdrawal  of
consent of patients randomized to the nucleoside free
treatment arm and protocol violation of patients who
were treated with nucleoside containing HAART de-
spite being randomized to nRTI free HAART. This
may have introduced a bias leaving only highly moti-
vated  patients  in  this  treatment  arm.  despite  taking
potential confounders into account we could not ad-
just for adherence as we did not capture this data and
therefore our findings to this regard must be consid-
ered with caution. However, even taking the nine pa-
tients with protocol violation into account, in the in-
tent-to-treat analysis there was still an almost 20% dif-
ference in the rate of SvR between patients on nRTI
containing and nRTI free HAART. In addition, it is
quite suggestive that a nucleoside free HAART may be
of potential benefit, as higher rates of toxicity have
been  reported  in  patients  receiving  didanosine,  zi-
dovudine or stavudine and SvR rates were compro-
mised by concomitant therapy with abacavir. Recently
Pineda et al. investigated into the impact of different
HAART regimens on the rate of SvR in a large obser-
vational retrospective cohort. In this study an nnRTI
or PI based HAART with tenofovir or stavudine plus
lamivudine  as  nucleoside  backbone  showed  signifi-
cantly higher response rates (44% vs. 29%) compared
to other nucleoside combinations [29]. These observa-
tions are in line with our study, though the group of
patients on a nucleoside containing HAART was too
small to detect a potential benefit of a tenofovir con-
taining  nucleoside  backbone  as  part  of  HAART.  In
summary,  our  study  revealed  that  a  nucleoside-free
HAART is feasible in the context of anti-Hcv thera-
py and that it was at the least not disadvantageous for
our patients. on the contrary, nucleoside-free HAART
may offer great improvements of treatment response
rates, which should be further studied in future treat-
ment trials. 
concluSIon
With modern pegylated interferon and ribavirin thera-
py similar response rates may be achieved among HIv-
negative  and  HIv-positive  patients.  While  pegylated
interferon and ribavirin therapy without HAART led
to  fewer  hematologic  adverse  events,  rates  of  sus-
tained virological response were similar between HIv-
positive patients on HAART and off HAART. Avoid-
ing nucleosides as part of HAART for the duration of
anti-Hcv  therapy  may  offer  great  opportunities  to
further enhance treatment response rates and should
be explored in more detail in future studies. 
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